Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma.
Acute nonlymphocytic leukemia (ANLL) developed in 2 of 142 pediatric patients with osteosarcoma treated with a cis-diamminedichloroplatinum-II (CDP)-based regimen: acute monomyelogenous leukemia (M4) with a normal female karyotype in one and acute myelogenous leukemia (M2) with t (8,21) in the other. The ANLLs occurred, respectively, in each patient 3 and 4 years after the initial diagnosis of osteosarcoma. In contrast to most of the adult experience and consistent with the majority of reported ANLL in children, the disease was characterized by an absence of the smoldering phase and cytogenetic findings similar to those seen in de novo ANLL.
Jeha
S
S
Department of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Jaffe
N
N
Robertson
R
R
D000293:Adolescent; D002648:Child; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012516:Osteosarcoma / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate